Enter the e-mail address you used when you registered an account with IIR Energy.
A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.
India's biopharmaceutical major Biocon Limited said its subsidiary Biocon Biologics Limited has received approval from the Drugs Controller General of India (DCGI) for its extracorporeal blood purification (EBP) device, CytoSorb, which could help reduce pro-inflammatory cytokines levels in critical COVID-19 patients.
According to a Biocon media release, the license will be effective until the COVID-19 outbreak is controlled in the country and will be used as an emergency therapy to treat COVID-19 patients who are 18 or above and are being treated in the intensive care unit (ICU) with confirmed or imminent respiratory failure. Industrial Info is tracking 19 projects from Biocon and its subsidiaries worth $224.57 million. Click here for a list and see map below.
|Listen to Today's News||News Audio Library||Sync News Podcasts|
This article is free for all Registered Members.
Register Now! All Fields are Required...
Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361
All Members Receive the Following Free Resources: